For superficial infantile hemangiomas (superficial hemangiomas) that are in the proliferative phase within 1 year of age, early topical medication (small superficial HOIs should be treated in an early proliferative phase) can be used to control The hemangiomas should be treated in an early proliferative phase to control further development, promote regression, and relieve the psychological stress of the parents. Clinically available medications include 5% imiquimod cream, 0.5% timolol maleate eye drops, and propranolol oil or emulsion. The first successful treatment of a 4-month-old infant with epiphora hemangioma was reported by Ni et al. Chakkittakandiyil et al. Oranje et al. reported that topical application of 0.5% timolol maleate eye drops (1-4 months) treated 20 children, except for 3 cases with no improvement in deep hemangioma, and the remaining 7 children began to slowly regress after the lesion growth was controlled. Hu Li et al. compared the efficacy and safety of two topical drugs, 5% imiquimod cream and 0.5% timolol maleate eye drops, on superficial infantile hemangioma (IH) in the proliferative stage, and the topical 5% imiquimod cream group generally began to take effect 1 to 3 weeks after topical application, with a mean onset of effect of 14 days and a treatment efficiency of 81.4%. 0.5% timolol maleate eye drops took effect 3 d to 3 weeks after topical application, with a mean onset of effect of 8 days. The average onset of action was 8 days, with a treatment efficiency of 88.9%. After topical application of imiquimod cream, skin reactions may occur to varying degrees, including erythema, peeling, breakout, crusting and superficial scarring. It is believed that timolol maleate has a relatively rapid onset of action, promotes a higher degree of lesion color fading, and has fewer adverse effects, and can be the topical drug of choice for the treatment of proliferative superficial hemangiomas. The use of 0.5% timolol maleate eye drops: 3 times a day at an interval of 8 h. Apply the drops to the surface of the tumor with thin medical cotton or cosmetic sponge moistened with the drops and keep it moist for 10 min, avoiding contact with the conjunctiva, mucous membrane of the mouth and nose, and perianal mucous membrane.